Craif develops biotechnology and artificial intelligence solutions for the early detection of cancer and other diseases. The company provides miSignal, a cancer risk testing service that analyzes biological signals in urine and saliva to identify indicators associated with cancer risk. Its technology focuses on microRNA and other biomolecules found in bodily fluids, using a biomarker analysis platform called NANO Intelligence Platform and AI algorithms to interpret these signals. Craif also develops medical devices and diagnostic technologies intended to support the early detection and diagnosis of diseases such as pancreatic cancer. Its research activities combine biotechnology, biomarker analysis, artificial intelligence, and clinical research to support preventive healthcare and individualized medical care.